Prostate Cancer
Prostate Cancer
Advertisement
Preston Sprenkle, MDProstate Cancer | March 24, 2023
Dr. Sprenkle shares his inspiration to practice urologic oncology and his role in popularizing the Artemis Device.
Read More
Amar Kishan, MDProstate Cancer | March 24, 2023
Amar Kishan, MD gives an overview of the MIRAGE trial that compared MRI-guided and CT-guided SBRT for prostate cancer.
David Ambinder, MDProstate Cancer | March 24, 2023
Can using a hyaluronic acid spacer mitigate rectal toxicity and reduce the gastrointestinal toxicity associated with RT?
Emily MenendezmCRPC | March 23, 2023
A recent study compared the activity of taxanes with second-line androgen-receptor therapy in patients with mCRPC.
Emily MenendezLocalized Prostate Cancer | March 21, 2023
A study arm from the phase 3 EMBARK trial evaluating enzalutamide for nmCSPC with high-risk BCR has had positive outcomes.
Emily MenendezNext-Generation Imaging | March 17, 2023
Researchers used determined if an increase in ACM risk existed when sRT was delivered above a prespecified PSA level.
Emily MenendezProstate Cancer | March 16, 2023
The new indication will improve access to imaging for approximately 32,000 candidates for radioligand therapy in the US.
Emily MenendezLocalized Prostate Cancer | March 13, 2023
A recent study analyzed a 15-year follow-up in men with prostate cancer to gauge the effectiveness of different treatments.
Emily MenendeznmCRPC | March 10, 2023
Researchers conducted a study to determine PSA response and MFS in patients with nmCRPC treated with APA.
Akhil Abraham Saji, MDProstate Cancer | March 10, 2023
Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer.
Rachelle Rodriguez, MS, APRN, AOCNPExpert Interviews | March 6, 2023
Rachelle Rodriguez, MS, APRN, AOCNP, highlights her role in helping Moffitt grow its APP presence within the GU onc program.
Akhil Abraham Saji, MDLocalized Prostate Cancer | February 28, 2023
This review highlights the research on the costs related to the treatment of localized PC and the associated outcomes.
Phouc T. Tran, MD, PhDASCO GU Symposium 2023 | February 24, 2023
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
David Ambinder, MDProstate Cancer | February 23, 2023
It is increasingly common for patients with favorable intermediate-risk PC to be managed with active surveillance.
David Ambinder, MDProstate Cancer | February 23, 2023
Implementing sterilization techniques may reduce infectious complications associated with transrectal prostate biopsy.
David Ambinder, MDmHSPC | February 23, 2023
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Siddharth Ramanathan and Savitha Balaraman, MDProstate Cancer | February 23, 2023
Siddharth Ramanathan and Savitha Balaraman, MD, highlight an onsite genetic testing protocol for newly diagnosed with PC.
Howard Korman, MD, and Savitha Balaraman, MDProstate Cancer | February 23, 2023
Drs. Howard Korman and Savitha Balaraman describe the importance of genetic testing for patients newly diagnosed with PC.
Oncology BrothersOncology Brothers | February 22, 2023
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Scott Tagawa, MD, MS, FACPRLT-PSMA | February 22, 2023
Scott Tagawa, MD, MS, FACP, shares what needs to happen for radionuclide therapy to make its way into the community setting.
Advertisement
Advertisement
Advertisement